Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Provided By GlobeNewswire
Last update: Aug 11, 2025
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025.
Read more at globenewswire.com
